DUBLIN--(BUSINESS WIRE)--The "NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034" drug pipelines has been added to ResearchAndMarkets.com's offering.
Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of all newly diagnosed cases.
The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.
Recent events and opinion
- Market growth will be driven by increasing disease prevalence and the approval of pipeline therapies targeted at patient populations with unmet needs.
- R-CHOP chemotherapy remains the standard of care first-line treatment for DLBCL.
- Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
- Rituxan remains the standard of care in the treatment of DLBCL and is likely to face biosimilar erosion upon patent expiry.
- The DLBCL late-stage pipeline has shrunk dramatically after the suspension of three Phase III trials.
Key Topics Covered:
Forecast: Diffuse Large B-Cell Lymphoma
Market Overview And Trends
Market Definition And Methodology
Primary Research Methodology
Treatment: Diffuse Large B-Cell Lymphoma
Disease Definition And Diagnosis
Country Treatment Trees
Current Treatment Options
Epidemiology: Diffuse Large B-Cell Lymphoma
Appendix: Additional Sources
Marketed Drugs: Diffuse Large B-Cell Lymphoma
Product Profile: Rituxan
Pipeline: Diffuse Large B-Cell Lymphoma
Clinical Pipeline Overview
Target Product Profile
Recently Discontinued Drugs
Product Profile (Late Stage): Imbruvica
Product Profile (Late Stage): Keytruda
Product Profile (Late Stage): Revlimid
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rlfcs4/nhl_diffuse?w=4